Family Medicine

GENetic Education Risk Assessment and TEsting Study

Condition:   Candidates for Hereditary Pancreatic Cancer Testing
Interventions:   Other: Doxy.me genetic education +/- Color Genomics genetic education;   Other: Color Genomics genetic education
Sponsors:   Dana-Farber Cancer Institute;   M.D. Anderson Cancer Center;   Johns Hopkins University;   University of California, San Diego;   Mayo Clinic;   Weill Cornell Medicine;   Stand Up To Cancer;   Lustgarten Foundation
Not yet recruiting
ClinicalTrials.gov: Family_Medicine | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 4, 2018 / by / in
Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer

Conditions:   Endometrial Undifferentiated Carcinoma;   Endometrioid Adenocarcinoma;   Recurrent Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IV Uterine Corpus Cancer AJCC v7;   Stage IVA Uterine Corpus Cancer AJCC v7;   Stage IVB Uterine Corpus Cancer AJCC v7
Interventions:   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib
Sponsor:   National Cancer Institute (NCI)
Recruiting
ClinicalTrials.gov: Family_Medicine | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 1, 2018 / by / in
Natural History Study of Patients With Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency

Condition:   Succinic Semialdehyde Dehydrogenase Deficiency
Interventions:   Device: Transcranial magnetic stimulation (TMS);   Device: Magnetic resonance imaging (MRI);   Device: Electroencephalogram (EEG);   Procedure: Bio-specimen Collection
Sponsors:   Boston Children’s Hospital;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Washington State University;   University of South Florida;   University Hospital Heidelberg
Not yet recruiting
ClinicalTrials.gov: Family_Medicine | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

November 30, 2018 / by / in
Harms of Hepatocellular Carcinoma Surveillance

Condition:   Carcinoma, Hepatocellular
Interventions:   Other: Prospective Longitudinal Data;   Other: Surveys and Semi-structured Interviews
Sponsors:   University of Texas Southwestern Medical Center;   National Cancer Institute (NCI);   Parkland Health & Hospital System;   Baylor College of Medicine;   Michael Debakey Veterans Affairs Medical Center;   Kaiser Permanente
Not yet recruiting
ClinicalTrials.gov: Family_Medicine | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

November 29, 2018 / by / in
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL

Conditions:   B-Cell Acute Lymphoblastic Leukaemia;   ALL, Adult;   B-ALL
Interventions:   Drug: Blinatumomab;   Other: Haplo-Mismatched Cell Therapy (HMCT)
Sponsors:   Cedars-Sinai Medical Center;   Amgen
Not yet recruiting
ClinicalTrials.gov: Family_Medicine | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

November 27, 2018 / by / in